Strong 400% stock appreciation over the past year, positive Phase 3 psoriasis trial results with high PASI response rates, solid cash position ($569.5M) funding operations into late 2027, upcoming NDA submission in Q4 2026, and continued institutional buying by Cormorant signal confidence in the company's pipeline and commercial potential.
The company reported strong Phase 3 clinical trial results for envudeucitinib with high efficacy rates (68% PASI 90, 41% PASI 100 at Week 24), early symptom relief, favorable safety profile, and plans for FDA NDA submission in H2 2026. These results support the drug's potential as a leading oral therapy for plaque psoriasis and validate the TYK2 inhibition mechanism.
Articles that tag ALMS but are mainly about other companies.
Announced positive topline results from Phase III ONWARD1 and ONWARD2 trials of envudeucitinib (TYK2 inhibitor) in January 2026, indicating strong clinical efficacy and potential for market entry.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
